Published : Jan-2019
No. of Pages : 201
1.1 List of Tables
1.2 List of Figures
2 Rheumatoid Arthritis: Executive Summary
2.1 Biosimilar Erosion Will Temper Sales Growth in the RA Market from 2017-2027
2.2 Development of Novel Oral Agents and Biosimilars Are Popular R&D Strategies
2.3 Opportunities Remain for More Rapid, Targeted, and Cost-Effective Treatment for RA patients
2.4 Pipeline JAK1 Inhibitors Are Best Equipped to Penetrate the Crowded RA Market
2.5 What Do Physicians Think?
3 Introduction
3.1 Catalyst
3.2 Related Reports
4 Disease Overview
4.1 Etiology
4.2 Pathophysiology
4.3 Symptoms and Severity Classifications
5 Epidemiology
5.1 Disease Background
5.2 Risk Factors and Comorbidities
5.3 Global and Historical Trends
5.4 Forecast Methodology
5.5 Epidemiological Forecast for Rheumatoid Arthritis (2017-2027)
5.6 Discussion
6 Disease Management
6.1 Diagnosis and Treatment Overview
6.2 US
6.3 5EU
6.4 Japan
6.5 Australia
7 Competitive Assessment
7.1 Overview
7.2 Biosimilars in the RA Market
8 Unmet Needs and Opportunity Assessment
8.1 Overview
8.2 Earlier Diagnosis and Treatment
8.3 Cost-Effective Therapies
8.4 Personalized Treatment Strategies
8.5 Improved Guidance on Treating RA Patients in Remission
9 Pipeline Assessment
9.1 Overview
9.2 Promising Drugs in Clinical Development
9.3 Other Drugs in Development
10 Current and Future Players
10.1 Overview
10.2 Trends in Corporate Strategy
10.3 Company Portfolio Assessments
11 Market Outlook
11.1 Global Markets
11.2 US
11.3 5EU
11.4 Japan
11.5 Australia
12 Appendix
12.1 Bibliography
12.2 Abbreviations
12.3 Methodology
12.4 Primary Research - KOLs and Payers Interviewed for This Report
12.5 Primary Research - Prescriber Survey
12.6 About the Authors
12.7 About GlobalData
12.8 Contact Us
12.9 Disclaimer
1.1 List of Tables
Table 1: RA: Key Metrics in the 8MM
Table 2: RA Disease Severity Classification
Table 3: Risk Factors and Comorbidities of RA
Table 4: 1987 ACR Diagnostic Criteria for RA
Table 5: Classification Criteria for Rheumatoid Arthritis - ACR 1987
Table 6: Classification Criteria for Rheumatoid Arthritis - ACR/EULAR 2010
Table 7: Treatment Guidelines for RA throughout the 8MM, 2018
Table 8: ACR/EULAR Diagnostic Definitions of Remission in RA Clinical Trials
Table 9: Country Profile - US
Table 10: Regional Profile - 5EU
Table 11: Country Profile - Japan
Table 12: Country Profile - Australia
Table 13: Leading Branded Treatments for RA, 2018
Table 14: Marketed Biosimilars for RA, 2018
Table 15: Pipeline Biosimilars for RA, 2018
Table 16: Average Percent Discount on Biosimilars Compared to Biologic Reference Products Across the 8MM, 2017
Table 17: AbbVie's RA Portfolio Assessment, 2018
Table 18: Pfizer's RA Portfolio Assessment, 2018
Table 19: Amgen's RA Portfolio Assessment, 2018
Table 20: J&J's RA Portfolio Assessment, 2018
Table 21: BMS' RA Portfolio Assessment, 2018
Table 22: Roche/Genentech's RA Portfolio Assessment, 2018
Table 23: Eli Lilly's RA Portfolio Assessment, 2018
Table 24: UCB's RA Portfolio Assessment, 2018
Table 25: Sanofi's RA Portfolio Assessment, 2018
Table 26: Astellas' RA Portfolio Assessment, 2018
Table 27: Gilead's RA Portfolio Assessment, 2018
Table 28: Galapagos' RA Portfolio Assessment, 2018
Table 29: R-Pharm's RA Portfolio Assessment, 2018
Table 30: Taisho's RA Portfolio Assessment, 2018
Table 31: Can-Fite's RA Portfolio Assessment, 2018
Table 32: RA Market - Global Drivers and Barriers, 2017-2027
Table 33: Key Events Impacting Sales for RA in the US, 2017-2027
Table 34: RA Market - Drivers and Barriers in the US, 2017-2027
Table 35: Key Events Impacting Sales for RA in the 5EU, 2017-2027
Table 36: RA Market - Drivers and Barriers in the 5EU, 2017-2027
Table 37: Key Events Impacting Sales for RA in Japan, 2017-2027
Table 38: RA Market - Global Drivers and Barriers in Japan, 2017-2027
Table 39: Key Events Impacting Sales for RA in Australia, 2017-2027
Table 40: RA Market - Global Drivers and Barriers in Australia, 2017-2027
Table 41: Key Historical and Projected Launch Dates for RA
Table 42: Key Historical and Projected Patent/Exclusivity Expiry Dates for RA
Table 43: High-Prescribing Physicians (non-KOLs) Surveyed, By Country
1.2 List of Figures
Figure 1: Global Sales Forecast by Country for RA in 2017 and 2027
Figure 2: Analysis of the Company Portfolio Gap in RA During the Forecast Period
Figure 3: Competitive Assessment of the Late-Stage Pipeline Agents That GlobalData Expects to Be Licensed for the Treatment of RA During the Forecast Period
Figure 4: Overview of RA Pathogenesis and Pathophysiology
Figure 5: Cellular and Cytokine Targets for the Marketed and Late-Stage Pipeline RA Drugs
Figure 6: 8MM, Age-Standardized Diagnosed Incidence of RA (Cases per 100,000 Population), Both Sexes, Ages ?18 Years, 2017
Figure 7: 8MM, Age-Standardized Diagnosed Prevalence of RA (%), Men, Ages ?18 Years, 2007 to 2027
Figure 8: 8MM, Age-Standardized Diagnosed Prevalence of RA (%), Women, Ages ?18 Years, 2007 to 2027
Figure 9: 8MM, Age-Standardized Total Prevalence of RA (%), Men, Ages ?18 Years, 2007 to 2027
Figure 10: 8MM, Age-Standardized Total Prevalence of RA (%), Women, Ages ?18 Years, 2007 to 2027
Figure 11: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of RA
Figure 12: 8MM, Sources Used to Forecast the Diagnosed Prevalent Cases of RA
Figure 13: 8MM, Sources Used to Forecast the Total Prevalent Cases of RA
Figure 14: 8MM, Diagnosed Incident Cases of RA, Both Sexes, Ages ?18 Years, N, 2017
Figure 15: 8MM, Age-Specific Diagnosed Incident Cases of RA, Both Sexes, Ages ?18 Years, N, 2017
Figure 16: 8MM, Sex-Specific Diagnosed Incident Cases of RA, Ages ?18 Years, N, 2017
Figure 17: 8MM, Diagnosed Prevalent Cases of RA, Both Sexes, Ages ?18 Years, N, 2017
Figure 18: 8MM, Age-Specific Diagnosed Prevalent Cases of RA, Both Sexes, Ages ?18 Years, N, 2017
Figure 19: 8MM, Sex-Specific Diagnosed Prevalent Cases of RA, Ages ?18 Years, N, 2017
Figure 20: 8MM, Diagnosed Prevalent Cases of RA By Severity, Both Sexes, Ages ?18 Years, N, 2017
Figure 21: 8MM, Total Prevalent Cases of RA, Both Sexes, Ages ?18 Years, N, 2017
Figure 22: 8MM, Age-Specific Total Prevalent Cases of RA, Both Sexes, Ages ?18 Years, N, 2017
Figure 23: 8MM, Sex-Specific Total Prevalent Cases of RA, Ages ?18 Years, N, 2017
Figure 24: General Treatment Algorithm for RA Patients
Figure 25: Physicians Reporting Prescription of Biosimilars to at Least 25%, 50%, or 75% of Their RA Patients Throughout the 8MM, 2018
Figure 26: Physicians Reporting Prescription of Biosimilars to at Least 50% of Their RA Patients Throughout the 5EU, 2018
Figure 27: Prescription of Etanercept, Infliximab, and Rituximab Biosimilars in Comparison to Reference Biologics Among 5EU Physicians, 2017
Figure 28: Unmet Needs and Opportunities in RA, 2018
Figure 29: Overview of the Development Pipeline in RA
Figure 30: Key Phase II/III Trials for the Promising Pipeline Agents That GlobalData Expects to Be Licensed for RA in the 8MM During the Forecast Period
Figure 31: Competitive Assessment of the Late-Stage Pipeline Agents That GlobalData Expects to Be Licensed for the Treatment of RA During the Forecast Period, 2017-2027
Figure 32: Analysis of the Company Portfolio Gap in RA During the Forecast Period
Figure 33: Global (8MM) Sales Forecast by Country for RA in 2017 and 2027
Figure 34: Global (8MM) Sales Forecast for RA, by Class, in 2017 and 2027
Figure 35: Sales Forecast by Class for RA in the US in 2017 and 2027
Figure 36: Sales Forecast by Class for RA in the 5EU in 2017 and 2027
Figure 37: Sales Forecast by Class for RA in Japan in 2017 and 2027
Figure 38: Sales Forecast by Class for RA in Australia in 2017 and 2027
